BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 2.39B |
| Revenue (ttm) | 77.65M |
| Net Income (ttm) | -481.18M |
| Shares Out | 160.20M |
| EPS (ttm) | -3.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,501,471 |
| Open | 13.60 |
| Previous Close | 13.58 |
| Day's Range | 11.75 - 14.90 |
| 52-Week Range | 4.98 - 19.95 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | 23.69 (+58.99%) |
| Earnings Date | May 4, 2023 |
About BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 cli... [Read more]
Financial Performance
In 2022, BBIO's revenue was $77.65 million, an increase of 11.38% compared to the previous year's $69.72 million. Losses were -$481.18 million, -14.46% less than in 2021.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is $23.69, which is an increase of 58.99% from the latest price.
News
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO® (nivolumab)
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continu...
BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why
Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of...
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
- BridgeBio has developed a validated bioassay that directly measures glycosylated ⍺ DG, which is central to LGMD2I disease, and enables monitoring of responses to disease-modifying therapies in LGMD2...
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expect...
BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope
The Palo Alto-based company's susceptibility to extreme price swings was on display again last week, albeit on a smaller scale. Positive results in a study of BridgeBio's infigratinib candidate sent t...
Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year?
Here is how BridgeBio Pharma (BBIO) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today a...
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announc...
Why Is BridgeBio Pharma (BBIO) Stock Up 60% Today?
There's potentially good news for the medical community and definitely positive news for investors of BridgeBio Pharma (NASDAQ: BBIO) stock. Reportedly, BridgeBio Pharma published clinical results fr...
BridgeBio's stock rallies 50% on new data from dwarfism therapy
Shares of BridgeBio Pharma Inc. BBIO, -0.09% soared about 52% in premarket trading on Monday after the company shared positive data from a Phase 2 clinical trial about its experimental treatment for a...
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
PALO ALTO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today ann...
Does BridgeBio Pharma (BBIO) Have the Potential to Rally 67.36% as Wall Street Analysts Expect?
The consensus price target hints at a 67.4% upside potential for BridgeBio Pharma (BBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.16% and 84.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...
Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...
BridgeBio Pharma to Participate in February and March Investor Events
PALO ALTO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...
BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...
BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations ove...
BridgeBio Pharma to Participate in November Investor Events
PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...
BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
- Reported positive preclinical data for its next-generation KRAS G12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization
Will BridgeBio Pharma (BBIO) Report Negative Q3 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium
- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRAS G12C GTP/GDP dual inhibitor development candidate BBO-8...